S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed mantle cell lymphoma (MCL) meeting the following criteria:
• •* Stage III-IV or bulky stage II disease
• •* Confirmation of positivity for the following phenotypes by immunohistochemistry or flow cytometry:
• •* Cluster of differentiation antigen 19 (CD19) (or CD20)
• •* Cyclin D1 OR evidence of t(11;14) translocation by cytogenetic analysis or fluorescent in situ hybridization
• •Newly diagnosed, previously untreated disease
• •Bidimensionally measurable disease by conventional techniques
• •* No nonmeasurable disease only
• •Adequate tumor tissue from original diagnostic specimen available
• •* Tissue obtained by needle aspiration or cytology not allowed
• •No clinical evidence of central nervous system (CNS) involvement by lymphoma
• •Co-registration on protocols SWOG-8947 and SWOG-8819 is strongly encouraged
• •PATIENT CHARACTERISTICS:
• •Zubrod performance status 0-2
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No peripheral neuropathy ≥ grade 2
• •No hypersensitivity to bortezomib, boron, or mannitol
• •No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or any other cancer for which the patient has been disease free for the past 5 years
• •HIV negative
• •PRIOR CONCURRENT THERAPY:
• •No prior chemotherapy, radiotherapy, or antibody therapy for lymphoma
• •More than 14 days since prior investigational drugs